Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
10 March 2022 - 10:10PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of March 2022
Commission File Number: 001-39179
Addex Therapeutics Ltd
(Translation of registrant's name into English)
Chemin des Mines 9,
CH-1202 Geneva,
Switzerland
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ] Form 40-F [ ]
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
On March 10, 2022, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
(c) Exhibit 99.1. Press release dated March 10, 2022
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| | Addex Therapeutics Ltd |
| | (Registrant) |
| | |
| | |
Date: March 10, 2022 | | /s/ Tim Dyer |
| | Tim Dyer |
| | Chief Executive Officer |
| | |
EXHIBIT INDEX
Addex Therapeutics (NASDAQ:ADXN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Addex Therapeutics (NASDAQ:ADXN)
Historical Stock Chart
From Jul 2023 to Jul 2024